GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Construction In Progress

Sinclair Pharma (XPAR:SPH) Construction In Progress : €0.00 Mil (As of Jun. 2018)


View and export this data going back to . Start your Free Trial

What is Sinclair Pharma Construction In Progress?


Sinclair Pharma Construction In Progress Historical Data

The historical data trend for Sinclair Pharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma Construction In Progress Chart

Sinclair Pharma Annual Data
Trend Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Dec17
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sinclair Pharma Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Jun17 Dec17 Jun18
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sinclair Pharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Sinclair Pharma (XPAR:SPH) Business Description

Traded in Other Exchanges
N/A
Address
Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.